PUREfi Wealth’s Royalty Pharma RPRX Stock Holding History

PUREfi Wealth’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$235K	Buy	+4,035	New	+$238K	0.11%	211

Other funds holding RPRX

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

New South Capital Management Memphis, Tennessee $1.53B AUM 36.31% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

PUREfi Wealth's RPRX Position: Q3 2026 in Review

PUREfi Wealth opened a new position in Royalty Pharma (RPRX) in Q3 2026: 4,035 shares worth $235K. The stake represents 0.11% of the portfolio and ranks #211 among its holdings.

318 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

PUREfi Wealth held 4,035 shares of Royalty Pharma worth $235K as of Q3 2026.
Royalty Pharma was a new PUREfi Wealth position in Q3 2026.
Royalty Pharma made up 0.11% of PUREfi Wealth's portfolio in Q3 2026, its #211 holding.
318 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on PUREfi Wealth's 13F filing for Q3 2026, filed 19 Oct 2026.